MET and clear cell renal carcinoma: Bioactive lncRNA activated in renal clear cell carcinoma (RCC) with Sunitinib resistance (lncARSR) incorporated into exosomes has been reported to induce resistance to Sunitinib when transferred to drug-sensitive cells, mainly by competitively binding to miR-34/miR-449 for enhancing the expression of AXL and c-MET expression in RCC cells47.